These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital. Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096 [TBL] [Abstract][Full Text] [Related]
23. Latent tuberculosis in childhood: tolerability of two different therapeutic approaches. Tersigni C; Venturini E; Cordola C; Piccini P; Bianchi L; Montagnani C; Sollai S; Chiappini E; de Martino M; Galli L Expert Rev Anti Infect Ther; 2018 Apr; 16(4):359-365. PubMed ID: 29465259 [TBL] [Abstract][Full Text] [Related]
24. Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults. Devrim I; Olukman O; Can D; Dizdarer C Chest; 2010 Mar; 137(3):737-8. PubMed ID: 20202962 [No Abstract] [Full Text] [Related]
25. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Kunst H; Khan KS Int J Tuberc Lung Dis; 2010 Nov; 14(11):1374-81. PubMed ID: 20937175 [TBL] [Abstract][Full Text] [Related]
26. Treatment of latent tuberculosis infection: a network meta-analysis. Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745 [TBL] [Abstract][Full Text] [Related]
27. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. Bliven EE; Podewils LJ Int J Tuberc Lung Dis; 2009 Sep; 13(9):1054-60. PubMed ID: 19723392 [TBL] [Abstract][Full Text] [Related]
28. Fluoroquinolones for the treatment of latent Silva JT; San-Juan R; Fernández-Ruiz M; Aguado JM World J Gastroenterol; 2019 Jul; 25(26):3291-3298. PubMed ID: 31341356 [TBL] [Abstract][Full Text] [Related]
29. A review of isoniazid-related hepatotoxicity during chemoprophylaxis. Stuart RL; Grayson ML Aust N Z J Med; 1999 Jun; 29(3):362-7. PubMed ID: 10868500 [No Abstract] [Full Text] [Related]
30. Treatment of latent tuberculosis infection: An update. Lobue P; Menzies D Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026 [TBL] [Abstract][Full Text] [Related]
31. Question 1: what are the options for treating latent TB infection in children? Gwee A; Coghlan B; Curtis N Arch Dis Child; 2013 Jun; 98(6):468-74. PubMed ID: 23661667 [No Abstract] [Full Text] [Related]
32. Antituberculosis drugs and hepatotoxicity. Yew WW; Leung CC Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297 [TBL] [Abstract][Full Text] [Related]
34. Fatal Isoniazid Hepatotoxicity in the Deployed Environment. Cybulski DJ; White BK Mil Med; 2021 May; 186(5-6):619-622. PubMed ID: 33128555 [TBL] [Abstract][Full Text] [Related]
35. Tuberculosis. Kelly AM Nurs Clin North Am; 2019 Jun; 54(2):193-205. PubMed ID: 31027661 [TBL] [Abstract][Full Text] [Related]
36. [Antitubercular drug-induced liver injuries]. Guo Y; Cui D Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):308-9. PubMed ID: 11326960 [No Abstract] [Full Text] [Related]
38. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. Hosford JD; von Fricken ME; Lauzardo M; Chang M; Dai Y; Lyon JA; Shuster J; Fennelly KP Tuberculosis (Edinb); 2015 Mar; 95(2):112-22. PubMed ID: 25595441 [TBL] [Abstract][Full Text] [Related]
39. Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature. Komai T; Sumitomo S; Teruya S; Fujio K Intern Med; 2018 Aug; 57(16):2413-2416. PubMed ID: 29526956 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Erwin ER; Addison AP; John SF; Olaleye OA; Rosell RC Tuberculosis (Edinb); 2019 May; 116S():S66-S70. PubMed ID: 31076322 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]